Sales & Marketing News | pharmaphorum

News

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s f

News

Roche’s Xolair is first medicine for food allergy in US

Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people w

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

News

FTC targets middlemen in generic drug shortages probe

The Federal Trade Commission (FTC) is asking for information from wholesalers and other middlemen in the pharmaceutical supply chain in an investigation into worsening sho

News

Grifols eyes first place in US fibrinogen concentrate market

Grifols is gearing up to file for approval of a drug for rare bleeding disorder acquired fibrinogen deficiency (AFD) that could provide a more reliable and easier treatmen

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

Roche’s Xolair is first medicine for food allergy in US

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

New era for cell therapy as FDA OKs first for solid tumours

FTC targets middlemen in generic drug shortages probe

Grifols eyes first place in US fibrinogen concentrate market

HHS doubles down on controversial peptides plan

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks